Citation

Ferris SH, Hofeldt GT, Carbone G, Masciandaro P, Troetel WM, Imbimbo BP. Alzheimer Dis. Assoc. Disord. 1999; 13(2): 88-90.

Affiliation

Silberstein Aging and Dementia Research Center, New York University School of Medicine, New York, USA.

Copyright

(Copyright © 1999, Lippincott Williams and Wilkins)

DOI

unavailable

PMID

10372951

Abstract

Two patients meeting the criteria for probable Alzheimer disease (AD) who were participating in a phase 3 clinical program with eptastigmine, a cholinesterase inhibitor, committed suicide. The first patient committed suicide by a self-inflicted gunshot wound to the head. The second patient committed suicide by jumping from a 19th story window. These two patients shared several clinical features with those found in the literature: being at the early stages of the disease, having a high level education, with preserved insight, having access to firearms, and being aware of not responding to pharmacological treatment.

Language: en